LSE · AZN.L
AstraZeneca PLC
£139.60+£9.08 (+6.96%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
Loading market information…
LSE · AGY.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 11:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Allergy Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 66.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Allergy Therapeutics plc’s next earnings report is currently expected on Mar 4, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Allergy Therapeutics plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:34 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £19.69M-73.75% vs estimate |
| Q2 2023 | Jun 19, 2023 | -£0.01-180.43% vs estimate | £39.90M0.0% vs estimate |
|---|
| Q4 2022 | Sep 29, 2022 | -£0.01-49.95% vs estimate | £24.10M0.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£139.60+£9.08 (+6.96%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
£18.55+£0.41 (+2.26%)
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 18.71% below the high.
£3.19+£0.02 (+0.54%)
Haleon plc’s quoted price sits in the lower half of its reported 52-week range, 26.34% below the high.
$37.12-$0.40 (-1.07%)
Roivant Sciences Ltd.’s quoted price sits in the upper half of its reported 52-week range, 12.66% below the high.
£11.08-£0.14 (-1.2%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 22.37% below the high.
£0.54£0.00 (0.0%)
Beximco Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 16.92% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
£0.03-£0.01 (-16.67%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 72.57% below the high.
